Briefing: DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

← SIGNALS[MONEY]
Briefing: DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC FilingStrategic angle: DAFNA Capital has made adjustments to its holdings in the iShares Biotechnology ETF as part of a broader strategy in the biotech sector.
Editorial Staff / March 21, 2026 / 1 MIN READ

On March 21, 2026, DAFNA Capital filed with the SEC, detailing modifications to its holdings in the iShares Biotechnology ETF.

These adjustments are part of a larger strategy aimed at optimizing their biotech portfolio.

The iShares Biotechnology ETF continues to play a significant role in DAFNA's investment framework, despite the recent changes.